Form 4: Cadrenal Therapeutics Director Acquires 20,000 Stock Options

Director Glynn Wilson of Cadrenal Therapeutics, Inc. acquired 20,000 stock options on January 23, 2025, which vest monthly over 12 months starting February 1, 2025.

Summary

• Glynn Wilson, a director at Cadrenal Therapeutics, Inc., was granted 20,000 stock options on January 23, 2025.
• These options have an exercise price of $19.79.
• The options vest pro rata on a monthly basis over 12 months, starting on February 1, 2025.
• The options expire on January 22, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows alignment of interests between the director and the company. It is not a major event, but it is a positive indicator.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders such as directors or officers make transactions in the company's securities. It is a routine disclosure required by law.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive packages.
• The vesting schedule of 12 months is also a typical arrangement to align the director's interests with the long-term performance of the company.
• The exercise price of $19.79 is a specific value for this grant and would need to be compared to other grants to determine if it is in line with industry standards.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's future.

Key Dates

Keywords

stock options, director, insider trading, Cadrenal Therapeutics, CVKD, equity, vesting